The combination of daptomycin with fosfomycin demonstrates increased efficacy in treating methicillin-resistant Staphylococcus aureus bacteremia compared with daptomycin alone.
The use of statins may decrease the risk for active tuberculosis.
A combination single tablet once-a-day regimen of doravirine/lamivudine/tenofovir disoproxil fumarate demonstrated non-inferiority and no significant adverse events when compared with continuation of established antiretroviral therapy in adults infected with HIV-1.
CAP guidelines recommend transitioning to an oral beta-lactam or fluoroquinolone regimen when patients are clinically stable, but because of common adverse effects, stewardship efforts are frequently focused on reducing initial fluoroquinolone use for CAP therapy.
The week 96 results of the DRIVE-AHEAD phase 3 noninferiority trial support noninferiority of doravirine to efavirenz in treatment-naive adults with HIV-1.
The trial enrolled 629 treatment-naïve adults living with HIV-1 and randomized them to receive Biktarvy (N=314) or ABC/DTG/3TC (N=315) with matching placebos.
Children who are HIV-exposed, but uninfected, demonstrated a higher risk of adverse neurologic events during infancy and early childhood associated with ART exposure in-utero.
Oral ciprofloxacin has been found to be an effective option for gram-negative bacteremia treatment.
The use of a moderate to low susceptibility antibiotic to treat a urinary tract infection [UTI] may result in a 1.74-fold increase in the odds of an emergency department readmission within 30 days for another UTI.
A documented β -lactam allergy was found in more than one-third of patients receiving broad-spectrum antibiotics, however, only 10% of patients were found to be truly allergic.
Please login or register first to view this content.
